{
  "_originalData": {
    "identity": {
      "bacteriumName": "Pseudomonas aeruginosa",
      "aliases": [],
      "lastUpdated": "2025-04-25",
      "clsiCategory": "Pseudomonas aeruginosa",
      "classification": {
        "gramStain": "Gram-negative",
        "morphology": "Bacillus",
        "respiration": "Aerobic",
        "notes": [
          "Glucose non-fermenter"
        ]
      },
      "strainDetails": [],
      "biochemicalTests": "Gram-negative rod, oxidase +, motile, non-lactose fermenter, produces pyocyanin (blue-green) and pyoverdin (fluorescent) pigments, grape-like odor, grows at 42Â°C."
    },
    "clinicalProfile": {
      "summary": "Causes a variety of local and systemic infections in both normal and immunocompromised hosts, including pneumonia (VAP, HAP), UTIs, and bloodstream infections. In neutropenic patients, it can cause ecthyma gangrenosum.",
      "pathophysiologyPearls": [],
      "keySignsAndSymptoms": [],
      "clinicalSyndromes": [
        {
          "syndromeName": "Pneumonia (VAP, HAP)",
          "description": "Ventilator-associated or hospital-acquired pneumonia."
        },
        {
          "syndromeName": "Urinary Tract Infection (UTI)",
          "description": "Infection of the urinary system."
        },
        {
          "syndromeName": "Bloodstream Infection",
          "description": "Presence of bacteria in the blood."
        },
        {
          "syndromeName": "Ecthyma Gangrenosum",
          "description": "A cutaneous necrotic lesion, typically seen in neutropenic patients."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Immunocompromised patients",
        "Neutropenic patients"
      ],
      "transmissionVectors": [],
      "prognosisNotes": []
    },
    "resistanceProfile": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [],
      "majorMechanisms": [
        {
          "mechanismName": "Loss of drug permeability",
          "mechanismType": "Efflux Pumps / Porin Loss",
          "description": "Due to multi-drug efflux pumps and/or loss of outer membrane porins. A common cause of carbapenem resistance."
        },
        {
          "mechanismName": "AmpC Beta-lactamase",
          "mechanismType": "Enzymatic Inactivation",
          "description": "Most common beta-lactamase. Hydrolyzes penicillins, monobactams, and cephalosporins. Not inhibited by serine-beta-lactamase inhibitors."
        },
        {
          "mechanismName": "Extended-spectrum beta-lactamases (ESBL)",
          "mechanismType": "Enzymatic Inactivation",
          "description": "Hydrolyze anti-pseudomonal cephalosporins."
        },
        {
          "mechanismName": "Carbapenemases",
          "mechanismType": "Enzymatic Inactivation",
          "description": "Typically metallo-beta-lactamases (MBLs) or serine carbapenemases."
        },
        {
          "mechanismName": "Mutation of drug target",
          "mechanismType": "Target Modification",
          "description": "e.g., Fluoroquinolone resistance due to gyrase mutations."
        },
        {
          "mechanismName": "Aminoglycoside modifying enzymes",
          "mechanismType": "Enzymatic Inactivation",
          "description": "Inactivate aminoglycoside antibiotics."
        }
      ],
      "clinicalAlerts": []
    },
    "treatment": {
      "generalNotes": [
        "Recommendations are for therapy of moderately severe or severe infections.",
        "There is no value to continued combination therapy once in vitro susceptibility to an anti-pseudomonal beta-lactam or fluoroquinolone is documented.",
        "Combination therapy has potential benefits for empiric therapy in high-risk patients by increasing the likelihood of at least one active drug."
      ],
      "drugsToAvoid": [
        {
          "drugOrClass": "Ertapenem",
          "condition": "All infections",
          "reason": "Not active against P. aeruginosa."
        }
      ],
      "adjunctiveTherapies": [],
      "regimens": [
        {
          "context": {
            "type": "Empiric",
            "condition": "Moderately severe or severe infection",
            "patientPopulation": [
              "Adults"
            ],
            "isolateSource": ""
          },
          "recommendations": [
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Piperacillin-tazobactam",
                      "dose": "4.5 gm IV (over 4 hr)",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Choice of specific agent guided by local susceptibility patterns."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Ceftazidime",
                      "dose": "2 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Choice of specific agent guided by local susceptibility patterns."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Cefepime",
                      "dose": "2 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Choice of specific agent guided by local susceptibility patterns."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Meropenem",
                      "dose": "1-2 gm",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Consider higher dose infused over 3 hours for serious infections. Choice of specific agent guided by local susceptibility patterns."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Primary",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Ceftolozane-tazobactam",
                      "dose": "1.5 gm IV over 1 hr (non-pneumonia) or 3 gm IV over 1 hr (HAP/VAP)",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "Choice of specific agent guided by local susceptibility patterns."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Aztreonam",
                      "dose": "2 gm",
                      "route": "IV",
                      "frequency": "q6h",
                      "comments": "For severe IgE-mediated beta-lactam allergy."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Ciprofloxacin",
                      "dose": "400 mg",
                      "route": "IV",
                      "frequency": "q8h",
                      "comments": "For severe IgE-mediated beta-lactam allergy."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Levofloxacin",
                      "dose": "750 mg",
                      "route": "IV",
                      "frequency": "q24h",
                      "comments": "For severe IgE-mediated beta-lactam allergy."
                    }
                  ]
                }
              ]
            },
            {
              "preference": "Alternative",
              "strategy": "Monotherapy",
              "steps": [
                {
                  "step": 1,
                  "duration": "",
                  "drugs": [
                    {
                      "drugName": "Tobramycin",
                      "dose": "7 mg/kg",
                      "route": "IV",
                      "frequency": "q24h",
                      "comments": "Not first-line, option for severe allergy, not for single use outside UTI."
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "laboratoryProfile": {
      "testingIndications": [
        "Encourage use of rapid diagnostics to identify resistance mechanisms."
      ],
      "methodologyNotes": [],
      "recommendedPanel": [],
      "specialTests": [],
      "reportingRules": [],
      "antimicrobialBreakpoints": []
    },
    "additionalInformation": {
      "diagnosticNotes": {
        "summary": "",
        "biosafetyWarning": "",
        "methods": []
      },
      "preventionAndScreening": [],
      "treatmentLifecycle": [],
      "antimicrobialStewardship": [
        "For more on resistance, see Gram Negative Bacilli, Beta-lactam Resistance, Overview."
      ],
      "drugSpecificPearls": [
        {
          "drugName": "Cefiderocol",
          "pearl": "FDA-approved for complicated UTI with limited alternatives. In a trial for nosocomial pneumonia, all-cause mortality was higher in the cefiderocol arm (24.8%) vs best available therapy (18.4%), though not statistically significant."
        },
        {
          "drugName": "Ceftolozane-tazobactam",
          "pearl": "Highly active in vitro, including against many meropenem-resistant isolates. Emergence of resistance due to ampC mutations has been reported."
        }
      ],
      "guidelineReferences": [
        {
          "source": "IDSA",
          "citation": "Updated 2024 IDSA Guidelines",
          "summaryOrNote": "Guideline on treatment of resistant gram-negative infections (ESBL, AmpC, carbapenemase producers)."
        }
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "laboratoryProfile",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.340Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Pseudomonas aeruginosa"
    },
    "aliases": {
      "sources": [
        "identity.aliases"
      ],
      "value": []
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2025-04-25"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Gram-negative",
        "morphology": "Bacillus",
        "respiration": "Aerobic",
        "notes": [
          "Glucose non-fermenter"
        ]
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "Causes a variety of local and systemic infections in both normal and immunocompromised hosts, including pneumonia (VAP, HAP), UTIs, and bloodstream infections. In neutropenic patients, it can cause ecthyma gangrenosum.",
      "pathophysiologyPearls": [],
      "keySignsAndSymptoms": [],
      "clinicalSyndromes": [
        {
          "syndromeName": "Pneumonia (VAP, HAP)",
          "description": "Ventilator-associated or hospital-acquired pneumonia."
        },
        {
          "syndromeName": "Urinary Tract Infection (UTI)",
          "description": "Infection of the urinary system."
        },
        {
          "syndromeName": "Bloodstream Infection",
          "description": "Presence of bacteria in the blood."
        },
        {
          "syndromeName": "Ecthyma Gangrenosum",
          "description": "A cutaneous necrotic lesion, typically seen in neutropenic patients."
        }
      ],
      "stagesOfIllness": [],
      "highRiskPopulations": [
        "Immunocompromised patients",
        "Neutropenic patients"
      ],
      "transmissionVectors": [],
      "prognosisNotes": []
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "groupIntrinsicResistance": [],
      "intrinsicResistance": [],
      "majorMechanisms": [
        {
          "mechanismName": "Loss of drug permeability",
          "mechanismType": "Efflux Pumps / Porin Loss",
          "description": "Due to multi-drug efflux pumps and/or loss of outer membrane porins. A common cause of carbapenem resistance."
        },
        {
          "mechanismName": "AmpC Beta-lactamase",
          "mechanismType": "Enzymatic Inactivation",
          "description": "Most common beta-lactamase. Hydrolyzes penicillins, monobactams, and cephalosporins. Not inhibited by serine-beta-lactamase inhibitors."
        },
        {
          "mechanismName": "Extended-spectrum beta-lactamases (ESBL)",
          "mechanismType": "Enzymatic Inactivation",
          "description": "Hydrolyze anti-pseudomonal cephalosporins."
        },
        {
          "mechanismName": "Carbapenemases",
          "mechanismType": "Enzymatic Inactivation",
          "description": "Typically metallo-beta-lactamases (MBLs) or serine carbapenemases."
        },
        {
          "mechanismName": "Mutation of drug target",
          "mechanismType": "Target Modification",
          "description": "e.g., Fluoroquinolone resistance due to gyrase mutations."
        },
        {
          "mechanismName": "Aminoglycoside modifying enzymes",
          "mechanismType": "Enzymatic Inactivation",
          "description": "Inactivate aminoglycoside antibiotics."
        }
      ],
      "clinicalAlerts": []
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": [
        {
          "regimenId": "modern-0-0-0",
          "extractedFrom": "treatment.regimens[0].recommendations[0].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Piperacillin-tazobactam",
              "dose": "4.5 gm IV (over 4 hr)",
              "route": "IV",
              "frequency": "q8h",
              "duration": "",
              "comments": "Choice of specific agent guided by local susceptibility patterns.",
              "originalText": "Piperacillin-tazobactam 4.5 gm IV (over 4 hr) IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-0-1-0",
          "extractedFrom": "treatment.regimens[0].recommendations[1].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Ceftazidime",
              "dose": "2 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "",
              "comments": "Choice of specific agent guided by local susceptibility patterns.",
              "originalText": "Ceftazidime 2 gm IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-0-2-0",
          "extractedFrom": "treatment.regimens[0].recommendations[2].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Cefepime",
              "dose": "2 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "",
              "comments": "Choice of specific agent guided by local susceptibility patterns.",
              "originalText": "Cefepime 2 gm IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-0-3-0",
          "extractedFrom": "treatment.regimens[0].recommendations[3].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Meropenem",
              "dose": "1-2 gm",
              "route": "IV",
              "frequency": "q8h",
              "duration": "",
              "comments": "Consider higher dose infused over 3 hours for serious infections. Choice of specific agent guided by local susceptibility patterns.",
              "originalText": "Meropenem 1-2 gm IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-0-4-0",
          "extractedFrom": "treatment.regimens[0].recommendations[4].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "primary",
          "drugs": [
            {
              "drugName": "Ceftolozane-tazobactam",
              "dose": "1.5 gm IV over 1 hr (non-pneumonia) or 3 gm IV over 1 hr (HAP/VAP)",
              "route": "IV",
              "frequency": "q8h",
              "duration": "",
              "comments": "Choice of specific agent guided by local susceptibility patterns.",
              "originalText": "Ceftolozane-tazobactam 1.5 gm IV over 1 hr (non-pneumonia) or 3 gm IV over 1 hr (HAP/VAP) IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-0-5-0",
          "extractedFrom": "treatment.regimens[0].recommendations[5].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Aztreonam",
              "dose": "2 gm",
              "route": "IV",
              "frequency": "q6h",
              "duration": "",
              "comments": "For severe IgE-mediated beta-lactam allergy.",
              "originalText": "Aztreonam 2 gm IV q6h"
            }
          ]
        },
        {
          "regimenId": "modern-0-6-0",
          "extractedFrom": "treatment.regimens[0].recommendations[6].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Ciprofloxacin",
              "dose": "400 mg",
              "route": "IV",
              "frequency": "q8h",
              "duration": "",
              "comments": "For severe IgE-mediated beta-lactam allergy.",
              "originalText": "Ciprofloxacin 400 mg IV q8h"
            }
          ]
        },
        {
          "regimenId": "modern-0-7-0",
          "extractedFrom": "treatment.regimens[0].recommendations[7].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Levofloxacin",
              "dose": "750 mg",
              "route": "IV",
              "frequency": "q24h",
              "duration": "",
              "comments": "For severe IgE-mediated beta-lactam allergy.",
              "originalText": "Levofloxacin 750 mg IV q24h"
            }
          ]
        },
        {
          "regimenId": "modern-0-8-0",
          "extractedFrom": "treatment.regimens[0].recommendations[8].steps[0]",
          "context": {
            "type": "empiric",
            "condition": "Moderately severe or severe infection",
            "severity": "severe",
            "patientFactors": {
              "population": [
                "Adults"
              ],
              "labFindings": ""
            }
          },
          "preference": "alternative",
          "drugs": [
            {
              "drugName": "Tobramycin",
              "dose": "7 mg/kg",
              "route": "IV",
              "frequency": "q24h",
              "duration": "",
              "comments": "Not first-line, option for severe allergy, not for single use outside UTI.",
              "originalText": "Tobramycin 7 mg/kg IV q24h"
            }
          ]
        }
      ]
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile"
    ],
    "value": {
      "testingIndications": [
        "Encourage use of rapid diagnostics to identify resistance mechanisms."
      ],
      "methodologyNotes": [],
      "recommendedPanel": [],
      "specialTests": [],
      "reportingRules": [],
      "antimicrobialBreakpoints": []
    }
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}